The quarter cleared the market’s bar on both major metrics. Published expectations were roughly $1.23 for adjusted EPS and $703 million of revenue; Revvity delivered $1.41 and $729.7 million, respectively.
| Metric | Q2 2026 | Q2 2025 | Market reference |
|---|---|---|---|
| Revenue | $729.7M (Financial Statements) | $720.3M (Financial Statements) | ~$703M consensus |
| Pro forma revenue | $711.1M (Financial Statements) | $680.5M (Financial Statements) | — |
| Adjusted EPS | $1.41 (Supplemental EPS) | $1.18 (Supplemental EPS) | ~$1.23 consensus |
| Adjusted operating margin | 28.9% (Adjusted operating income) | 26.6% (Adjusted operating income) | — |
| Operating cash flow | $191.9M (Cash Flow statement) | $134.3M (Cash Flow statement) | — |
| FY 2026 adjusted EPS guidance | $5.30–$5.40 (Outlook) | — | Prior guide $5.20–$5.30 |
The EPS beat was real but partly assisted by a one-time tariff refund. Adjusted EPS included approximately $0.11 from tariff-related refunds, implying roughly $1.30 before that benefit—still above the approximately $1.23 consensus, but less of a clean underlying surprise. Adjusted operating income also included $16 million of tariff refunds (Financial Highlights).
Diagnostics carried the quarter while Life Sciences remained the weak spot. Diagnostics revenue rose 12% pro forma organically and adjusted margin expanded to 30.4% from 25.2%; Life Sciences declined 3% organically and margin slipped to 31.1% from 31.6% (Segment results). That mix makes the consolidated beat stronger than the underlying Life Sciences trend, but it also shows where the recovery is concentrated.
Management raised the full-year framework rather than merely repeating it. Pro forma revenue is now guided to $2.83–$2.86 billion, organic growth to 4%–5%, and adjusted EPS to $5.30–$5.40, versus the prior $5.20–$5.30 EPS range reported before the quarter. The higher outlook is the clearest forward-looking upgrade in the filing, although the company is reinvesting part of the tariff refund, which limits how much of the quarterly margin benefit carries forward.
The China IDX divestiture is more detail than surprise, not the core earnings signal. The planned sale had already been discussed, so the definitive agreement and pro forma presentation make the scope clearer rather than introducing a wholly new strategic direction. China IDX represented about 6% of 2025 revenue, and the transaction could generate up to $200 million subject to adjustments and closing conditions (China IDX divestiture; Pro Forma Financial Statements).
Read the original 8-K on SEC EDGAR ↗